Chr. Hansen

Chr. Hansen

5 Jul 2017

NIB signs loan to fund bioscience R&D in Denmark

The Nordic Investment Bank and the Danish bioscience company Chr. Hansen Holdings A/S have signed a EUR 50 million loan for the company’s 2017–2018 R&D programme.

Chr. Hansen Holding A/S’s research and development programme in 2017–2018 will focus on process optimisation and development of new innovative products. The programme includes more than 100 R&D projects, half of which are in the fresh dairy and cheese sector. The five-year maturity loan from NIB will fund part of the programme’s EUR 150 million budget.

Chr. Hansen is a pioneer in probiotics, and its portfolio features some of the most-documented bacterial strains. Its ongoing R&D programme is geared towards customer needs and employs leading technology to deliver unique microbial solutions for a wide range of industries.

Founded in 1874, Danish Chr. Hansen is a global supplier of bioscience-based ingredients to the food, health and animal feed industries. The company produces cultures and dairy enzymes, probiotics and natural colours.

NIB is an international financial institution owned by eight member countries: Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway and Sweden. The Bank finances private and public projects in and outside the member countries. NIB has the highest possible credit rating, AAA/Aaa, with the leading rating agencies Standard & Poor’s and Moody’s.

For further information, please contact
Mr Vagn Lundhøj, Senior Manager, Origination, at +358 10 618 0370,

Ms Iben Hjorth, Communications Unit, at +358 10 618 0235,